Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL04
- Pharmacological subgroupL04A
- Chemical subgroupL04AJ
- Chemical substanceL04AJ03Pegcetacoplan
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Brazil
Anvisa · 2 registrations
European Union
EMA · 2 registrations
United States
FDA · 2 registrations
Canada
Health Canada · 1 registration
At a glance
- ATC code
- L04AJ03
- Registers
- 7
- Historical lists
- 1
- Registrations
- 12
- With their own page
- 8
- Companies
- 9
All medicines with Pegcetacoplan
Human medicines from every register that match Pegcetacoplan by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
12 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Empaveli | United States | 1080MG/20ML | solution | Marketed | Apellis Pharms |
| Syfovre | United States | 15MG/0.1ML | solution | Marketed | Apellis Pharms |
| Aspaveli 1080 MG Solucion Para Perfusion | Spain | 54 mg | solución para perfusión | Marketed | Swedish Orphan Biovitrum Ab (Publ) |
| Aspaveli | European Union | Authorised | Swedish Orphan Biovitrum AB (publ) | ||
| Aspaveli 1080 mg oplossing voor infusie | Netherlands | Oplossing voor infusie | Authorised | Apellis Ireland Limited | |
| Empaveli | Canada | 1080 MG / 20 ML | Solution | Marketed | Swedish Orphan Biovitrum AB (Publ) |
| Empaveli | Brazil | Authorised | Pint Pharma Produtos Medico-Hospitalares e Farmaceuticos Ltda | ||
| Aspaveli | Croatia | Marketed | |||
| Empaveli 1080 mg per 20 ml | Saudi Arabia | Authorised | Cangene BioPharma Inc. (CBI) | ||
| Empaveli 1080 mg per 20 ml 8 vials | Saudi Arabia | Authorised | Cangene BioPharma Inc. (CBI) | ||
| Syfovre | European Union | Refused | Apellis Europe B.V. | ||
| Empaveli | Brazil | Cancelled | Orphandc G Importacao e Distribuicao de Produtos Farmaceuticos Ltda |